Bringing New Energy to the Treatment of Type 2 Diabetes
Expanding treatment options for patients with Type 2 Diabetes
Consider studies for your patients with Type 2 Diabetes
Research shows that cells in the small intestine play an important role in modulating glucose homeostasis and that the duodenum is a meaningful therapeutic target in individuals with Type 2 Diabetes.7
The duodenum’s role as a therapeutic target
In patients with Type 2 Diabetes, cellular signaling in the duodenum has become abnormal, inhibiting the body’s ability to effectively manage blood glucose levels.8,9
Endogenex is committed to improving the treatment of Type 2 Diabetes
The ReCET Procedure is investigational and currently being evaluated in clinical studies. Endogenex is focused on shifting the treatment paradigm for people living with Type 2 Diabetes. Current diabetes care focuses on the downstream consequences of this metabolic disease by targeting insulin resistance with medications and insulin replacement therapy. Endogenex’s goal is to reset the cellular signaling of the duodenum to help the body better manage blood sugar levels.
Endogenex’s ReCETTM Technology applies the principle of metabolic change through Intestinal Cellular Regeneration (ICR) by eliminating poorly signaling cells and inducing regrowth of healthy signaling cells. ReCET’s use of non-thermal, pulsed electric fields allows for regeneration of the targeted cells without disruption of the extra-cellular matrix.
Regeneration of these cells is intended to restore proper metabolic signaling, improve the body’s ability to manage blood glucose levels and potentially slow disease progression.
The ReCET Procedure
The ReCET Catheter delivers highly controlled, non-thermal, pulsed electric fields to induce apoptosis and cellular regeneration. The endoscopic procedure takes a little over an hour to complete with same-day discharge for the patient.
“This [ReCET Procedure] could be a tremendous opportunity for people to have an outpatient, simple endoscopic procedure without pain and be able to control their diabetes.” — Paul Severson, M.D., Cuyuna Regional Medical Center
Become a clinical investigator
Endogenex is conducting clinical studies in the United States, Europe and Australia. Learn about these clinical studies and how you can get involved.